Related Experiment Video
Updated: Apr 12, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Long-Term Effects of Novel Combination Coating Anti-CD34 Antibody Applied on Sirolimus-Eluting Stents
Feng Chen1,2, Feng Yang2,3, Qian Zhao2,3
1Interventional Radiology Department, The First Affiliated Hospital of China Medical University, Shenyang, China.
Insights
The novel hyaluronan-chitosan and anti-CD34 antibody coating on sirolimus-eluting stents (HCASES) significantly improved endothelialization and reduced neointimal formation in porcine coronary arteries.
Area of Science:
- Biomaterials Science
- Cardiovascular Research
- Medical Device Technology
Background:
- Drug-eluting stents (DES) reduce restenosis but can delay re-endothelialization.
- Delayed endothelial healing is linked to later adverse vascular remodeling.
- Novel stent coatings aim to improve healing without compromising restenosis prevention.
Purpose of the Study:
- To evaluate a novel stent coating combining hyaluronan-chitosan (HC) and anti-CD34 antibody on sirolimus-eluting stents (HCASES).
- To assess HCASES for reduced neointimal formation and enhanced endothelialization compared to SES and anti-CD34 antibody stents (GS).
Main Methods:
- Three stent types (SES, GS, HCASES) were implanted in porcine coronary arteries (n=54).
- Stents were analyzed using scanning electron microscopy (SEM) and histology at 60, 90, and 120 days.
- Key endpoints included endothelial coverage and percentage of stenosis.
Main Results:
- HCASES demonstrated significantly higher endothelial coverage at 60 and 90 days compared to SES (P=0.03).
- At 120 days, HCASES and GS showed superior endothelial coverage versus SES (P=0.02).
- HCASES exhibited less stenosis than GS at 90 days (P<0.05), with comparable results to SES at 120 days.
Conclusions:
- The HCASES coating promotes long-term endothelialization.
- HCASES effectively reduces neointimal formation and inflammation.
- This combination coating represents a promising advancement in cardiovascular stent technology.
Objectives:
We investigated whether the combination coating of a novel "prohealing coating" hyaluronan-chitosan (HC) and anti-CD34 antibody applied on an SES (HCASES) can reduce neointimal formation while promoting endothelialization compared to either agent alone.
Background:
Drug-eluting stents have considerably reduced the incidence of in-stent restenosis compared with bare metal stents. However, the beneficial effect of drug elution is overshadowed by delayed re-endothelialization as well as later "catch-up" proliferation related to the drug.
Methods:
Three different stents: Sirolimus-eluting stents (SES), Genous anti-CD34 antibody stents (GS), and the combination of HC-anti-CD34 antibody with sirolimus-eluting stents (HCASES) were deployed in 54 normal porcine coronary arteries and harvested for scanning electron microscopy (SEM) and histological analysis at 60, 90, and 120 days.
Results:
At 60 and 90 days, SEM analysis showed stent surface endothelial coverage was nearly completed in the HCASES (87 ± 3%, 95 ± 3%) compared with that in the SES (68 ± 6%, 77 ± 8%, P = 0.03). Histological examination at 90 days showed that the HCASES group had less percentage of stenosis than the GS group (P < 0.05). At 120 days, SEM showed a significantly higher extent of endothelial coverage above struts in the HCASES (96 ± 2%) and the GS (95 ± 3%) as compared with the SES group (66 ± 3%; P = 0.02). The HCASES group showed less stenosis than that in the GS group (P < 0.05), but it was not significantly different from the SES group (P = 0.063).
Conclusions:
Histological and SEM analyses demonstrate that the HCASES can reduce neointimal formation and inflammation while promoting endothelialization in the long term.
